Dendritic cell therapy is an advanced immunotherapy that harnesses dendritic cells, the immune system’s key antigen-presenting cells to trigger a targeted immune response against kidney cancer (renal cell carcinoma, RCC)
Details →
Bladder cancer originates in the urothelial cells lining the bladder, with ~75% of cases being non-muscle invasive bladder cancer (NMIBC), confined to the mucosa or submucosa.
Details →
On the other hand, melanoma arises from melanocytes, the pigment-producing cells in the skin, and is significantly more dangerous due to its tendency to spread rapidly to other parts of the body.
Details →
Dendritic cell immunotherapy mobilizes dendritic cells, the immune system’s sentinels, to present leukemia-specific antigens to T-cells, sparking a precise attack on cancer cells.
Details →
Testicular cancer, a rare but treatable malignancy, impacts young men most often, demanding innovative and effective solutions for lasting recovery.
Details →
